WO2003042357A3 - Enzymes - Google Patents

Enzymes Download PDF

Info

Publication number
WO2003042357A3
WO2003042357A3 PCT/US2002/031096 US0231096W WO03042357A3 WO 2003042357 A3 WO2003042357 A3 WO 2003042357A3 US 0231096 W US0231096 W US 0231096W WO 03042357 A3 WO03042357 A3 WO 03042357A3
Authority
WO
WIPO (PCT)
Prior art keywords
enzm
enzymes
polynucleotides
agonists
diagnosing
Prior art date
Application number
PCT/US2002/031096
Other languages
French (fr)
Other versions
WO2003042357A2 (en
Inventor
Junming Yang
Dyung Aina M Lu
Henry Yue
Vicki S Elliott
Bridget A Warren
Brendan M Duggan
Ian J Forsythe
Ernestine A Lee
April J A Hafalia
Jayalaxmi Ramkumar
Original Assignee
Incyte Genomics Inc
Junming Yang
Dyung Aina M Lu
Henry Yue
Vicki S Elliott
Bridget A Warren
Brendan M Duggan
Ian J Forsythe
Ernestine A Lee
April J A Hafalia
Jayalaxmi Ramkumar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc, Junming Yang, Dyung Aina M Lu, Henry Yue, Vicki S Elliott, Bridget A Warren, Brendan M Duggan, Ian J Forsythe, Ernestine A Lee, April J A Hafalia, Jayalaxmi Ramkumar filed Critical Incyte Genomics Inc
Priority to AU2002347778A priority Critical patent/AU2002347778A1/en
Priority to JP2003544177A priority patent/JP2005525788A/en
Priority to US10/491,183 priority patent/US20050191627A1/en
Priority to EP02783990A priority patent/EP1434860A2/en
Priority to CA002460959A priority patent/CA2460959A1/en
Publication of WO2003042357A2 publication Critical patent/WO2003042357A2/en
Publication of WO2003042357A3 publication Critical patent/WO2003042357A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)

Abstract

Various embodiments of the invention provide human enzymes (ENZM) and polynucleotides which identify and encode ENZM. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of ENZM.
PCT/US2002/031096 2001-09-28 2002-09-26 Enzymes WO2003042357A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2002347778A AU2002347778A1 (en) 2001-09-28 2002-09-26 Enzymes
JP2003544177A JP2005525788A (en) 2001-09-28 2002-09-26 enzyme
US10/491,183 US20050191627A1 (en) 2001-09-28 2002-09-26 Enzymes
EP02783990A EP1434860A2 (en) 2001-09-28 2002-09-26 Enzymes
CA002460959A CA2460959A1 (en) 2001-09-28 2002-09-26 Enzymes

Applications Claiming Priority (24)

Application Number Priority Date Filing Date Title
US32638801P 2001-09-28 2001-09-28
US60/326,388 2001-09-28
US32897901P 2001-10-12 2001-10-12
US60/328,979 2001-10-12
US34603401P 2001-10-19 2001-10-19
US60/346,034 2001-10-19
US34828401P 2001-10-26 2001-10-26
US60/348,284 2001-10-26
US33804801P 2001-11-08 2001-11-08
US60/338,048 2001-11-08
US33234001P 2001-11-16 2001-11-16
US60/332,340 2001-11-16
US34035701P 2001-12-14 2001-12-14
US60/340,357 2001-12-14
US36879902P 2002-03-29 2002-03-29
US36872202P 2002-03-29 2002-03-29
US60/368,722 2002-03-29
US60/368,799 2002-03-29
US38155802P 2002-05-17 2002-05-17
US60/381,588 2002-05-17
US38711902P 2002-06-07 2002-06-07
US60/387,119 2002-06-07
US39066202P 2002-06-21 2002-06-21
US60/390,662 2002-06-21

Publications (2)

Publication Number Publication Date
WO2003042357A2 WO2003042357A2 (en) 2003-05-22
WO2003042357A3 true WO2003042357A3 (en) 2003-11-20

Family

ID=27583841

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/031096 WO2003042357A2 (en) 2001-09-28 2002-09-26 Enzymes

Country Status (5)

Country Link
EP (1) EP1434860A2 (en)
JP (1) JP2005525788A (en)
AU (1) AU2002347778A1 (en)
CA (1) CA2460959A1 (en)
WO (1) WO2003042357A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394330B2 (en) 2012-03-21 2016-07-19 Alios Biopharma, Inc. Solid forms of a thiophosphoramidate nucleotide prodrug
CN116083379B (en) * 2023-01-18 2024-09-27 安徽华恒生物科技股份有限公司 Transporter variant and application thereof in R-pantoic acid preparation

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005076012A2 (en) * 2004-01-30 2005-08-18 Five Prime Therapeutics, Inc. Novel splice variants and methods of use thereof
PL1642905T3 (en) * 2004-10-02 2009-04-30 Immatics Biotechnologies Gmbh Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
CA2598889A1 (en) * 2005-02-24 2006-08-31 Cemines, Inc. Compositions and methods for classifying biological samples
WO2008022153A2 (en) * 2006-08-14 2008-02-21 The Regents Of The University Of California Inhibitors of pde4 and methods of use
CN103209987B (en) 2010-09-22 2017-06-06 艾丽奥斯生物制药有限公司 Substituted nucleotide analog
AU2012358804B2 (en) 2011-12-22 2018-04-19 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
EP2827876A4 (en) 2012-03-22 2015-10-28 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
WO2015141761A1 (en) * 2014-03-21 2015-09-24 池田食研株式会社 Flavin-binding glucose dehydrogenase
JP7068287B2 (en) * 2016-10-13 2022-05-16 ビオメリュー Identification of pathogens in metagenomic samples and characterization of antibiotics
CN110749687B (en) * 2019-04-04 2021-05-28 中山大学 Schistosomiasis japonica early diagnosis urine biomarker and screening method and application thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EDGAR A.J. ET AL.: "Molecular cloning of the human and murine 2-amino-3-ketobutyrate coenzyme a ligase cDNAs", EUR. J. BIOCHEM., vol. 267, 2000, pages 1805 - 1812, XP002964897 *
SULLIVAN ET AL.: "Identification and characterization of the human homologue of the short PDE4A cAMP-specific phosphodiesterase RD1 (PDE4A1) by analysis of the human HSPDE4A gene locus located at chromosome 19p13.2", BIOCHEM. J., vol. 333, 1998, pages 693 - 703, XP002964896 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394330B2 (en) 2012-03-21 2016-07-19 Alios Biopharma, Inc. Solid forms of a thiophosphoramidate nucleotide prodrug
CN116083379B (en) * 2023-01-18 2024-09-27 安徽华恒生物科技股份有限公司 Transporter variant and application thereof in R-pantoic acid preparation

Also Published As

Publication number Publication date
JP2005525788A (en) 2005-09-02
CA2460959A1 (en) 2003-05-22
AU2002347778A1 (en) 2003-05-26
EP1434860A2 (en) 2004-07-07
WO2003042357A2 (en) 2003-05-22

Similar Documents

Publication Publication Date Title
WO2003052075A3 (en) Enzymes
WO2001098468A3 (en) Proteases
WO2003104410A3 (en) Enzymes
WO2002063005A3 (en) Lipid-associated molecules
WO2002008396A3 (en) Human proteases
WO2003033680A3 (en) Kinases and phosphatases
WO2002083709A3 (en) Kinases and phosphatases
WO2003042357A3 (en) Enzymes
WO2002038744A3 (en) Proteases
WO2002026950A3 (en) Transferases
WO2001071004A3 (en) Proteases
WO2002020736A3 (en) Proteases
WO2004003162A3 (en) Enzymes
WO2001046443A3 (en) Proteases
WO2003063769A3 (en) Vesicle-associated proteins
WO2002066646A3 (en) Neurotransmission-associated proteins
WO2003050084A3 (en) Kinases and phosphatases
WO2002064795A3 (en) Putative human enzymes
WO2003072729A3 (en) Enzymes
WO2002094780A3 (en) Kinases and phosphatases
WO2003031939A3 (en) Protein modification and maintenance molecules
WO2003093439A3 (en) Enzymes
WO2003083082A3 (en) Enzymes
WO2002083873A3 (en) Enzymes
WO2001083775A3 (en) Proteases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2460959

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003544177

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 10491183

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002783990

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002783990

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002783990

Country of ref document: EP